Blood MSI dynamics as a predictive biomarker of immune checkpoint inhibitor therapy efficacy in colorectal cancer (CRC): preliminary results from an observational trial

被引：0
|
作者：
Byakhova, M. [1 ]
Veselovsky, E. [1 ]
Yudina, V. [1 ]
Kuznetsova, O. [1 ]
Kravchuk, D. [1 ]
Lebedeva, A. [1 ]
Belova, E. [1 ]
Taraskina, A. [1 ]
Grigoreva, T. [1 ]
Kavun, A. [1 ]
Nikulin, V. [1 ]
Mileyko, V. [1 ]
Tryakin, A. [1 ]
Fedyanin, M. [1 ]
Ivanov, M. [1 ]
机构：
[1] City Clin Oncol Hosp 1, Novosibirsk, Russia
来源：
VIRCHOWS ARCHIV | 2024年 / 485卷
基金：
俄罗斯科学基金会;
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
E-PS-19-01
引用
收藏
页码：S422 / S422
页数：1
相关论文
共 50 条
  • [1] Evaluation of blood MSI burden dynamics to trace immune checkpoint inhibitor therapy efficacy through the course of treatment
    Veselovsky, Egor
    Lebedeva, Alexandra
    Kuznetsova, Olesya
    Kravchuk, Daria
    Belova, Ekaterina
    Taraskina, Anastasia
    Grigoreva, Tatiana
    Kavun, Alexandra
    Yudina, Victoria
    Belyaeva, Laima
    Nikulin, Vladislav
    Mileyko, Vladislav
    Tryakin, Alexey
    Fedyanin, Mikhail
    Ivanov, Maxim
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [2] ER expression as a predictive biomarker for Immune Checkpoint Inhibitor Therapy in ER positive breast cancer
    Arima, Jun
    Taniguchi, Kohei
    Inomata, Yosuke
    Hagihara, Seita
    Suzuki, Shigenori
    Lee, Sangwoong
    CANCER SCIENCE, 2025, 116 : 1149 - 1149
  • [3] The MITRE trial protocol: a study to evaluate the microbiome as a biomarker of efficacy and toxicity in cancer patients receiving immune checkpoint inhibitor therapy
    Thompson, Nicola A.
    Stewart, Grant D.
    Welsh, Sarah J.
    Doherty, Gary J.
    Robinson, Matthew J.
    Neville, B. Anne
    Vervier, Kevin
    Harris, Simon R.
    Adams, David J.
    Dalchau, Katy
    Bruce, David
    Demiris, Nikolaos
    Lawley, Trevor D.
    Corrie, Pippa G.
    BMC CANCER, 2022, 22 (01)
  • [4] The MITRE trial protocol: a study to evaluate the microbiome as a biomarker of efficacy and toxicity in cancer patients receiving immune checkpoint inhibitor therapy
    Nicola A. Thompson
    Grant D. Stewart
    Sarah J. Welsh
    Gary J. Doherty
    Matthew J. Robinson
    B. Anne Neville
    Kevin Vervier
    Simon R. Harris
    David J. Adams
    Katy Dalchau
    David Bruce
    Nikolaos Demiris
    Trevor D. Lawley
    Pippa G. Corrie
    BMC Cancer, 22
  • [5] Insight into immune checkpoint inhibitor therapy for colorectal cancer from the perspective of circadian clocks
    Liu, Yanhong
    Wang, Zeqin
    Hao, Hankun
    Wang, Yaping
    Hua, Luchun
    IMMUNOLOGY, 2023, 170 (01) : 13 - 27
  • [6] Predictive biomarkers of chemotherapy efficacy in colorectal cancer: Results from the UK MRC FOCUS trial
    Braun, Michael S.
    Richman, Susan D.
    Quirke, Philip
    Daly, Catherine
    Adlard, Julian W.
    Elliott, Faye
    Barrett, Jennifer H.
    Selby, Peter
    Meade, Angela M.
    Stephens, Richard J.
    Parmar, Mahesh K. B.
    Seymour, Matthew T.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (16) : 2690 - 2698
  • [7] Liver Metastases and Immune Checkpoint Inhibitor Efficacy in Patients With Refractory Metastatic Colorectal Cancer A Secondary Analysis of a Randomized Clinical Trial
    Chen, Eric X.
    Loree, Jonathan M.
    Titmuss, Emma
    Jonker, Derek J.
    Kennecke, Hagen F.
    Berry, Scott
    Couture, Felix
    Ahmad, Chaudharry E.
    Goffin, John R.
    Kavan, Petr
    Harb, Mohammed
    Colwell, Bruce
    Samimi, Setareh
    Samson, Benoit
    Abbas, Tahir
    Aucoin, Nathalie
    Aubin, Francine
    Koski, Sheryl
    Wei, Alice C.
    Tu, Dongsheng
    O'Callaghan, Chris J.
    JAMA NETWORK OPEN, 2023, 6 (12)
  • [8] Evolutionary genetic algorithm identifies IL2RB as a potential predictive biomarker for immune-checkpoint therapy in colorectal cancer
    Alderdice, Matthew
    Craig, Stephanie G.
    Humphries, Matthew P.
    Gilmore, Alan
    Johnston, Nicole
    Bingham, Victoria
    Coyle, Vicky
    Senevirathne, Seedevi
    Longley, Daniel B.
    Loughrey, Maurice B.
    McQuaid, Stephen
    James, Jacqueline A.
    Salto-Tellez, Manuel
    Lawler, Mark
    McArt, Darragh G.
    NAR GENOMICS AND BIOINFORMATICS, 2021, 3 (02)
  • [9] Plasma arginine as a predictive biomarker for outcomes with immune checkpoint inhibition in metastatic colorectal cancer: a correlative analysis of the CCTG CO.26 trial
    Ma, Lucy X.
    Titmuss, Emma
    Loree, Jonathan M.
    Jonker, Derek J.
    Kennecke, Hagen F.
    Berry, Scott
    Couture, Felix
    Ahmad, Chaudhary E.
    Goffin, John R.
    Kavan, Petr
    Harb, Mohammed
    Colwell, Bruce
    Samimi, Setareh
    Samson, Benoit
    Abbas, Tahir
    Aucoin, Nathalie
    Aubin, Francine
    Koski, Sheryl
    Tu, Dongsheng
    O'Callaghan, Christopher
    Chen, Eric X.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (12)
  • [10] Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort
    Anwaar Saeed
    Robin Park
    Harsh Pathak
    Ayah Nedal Al-Bzour
    Junqiang Dai
    Milind Phadnis
    Raed Al-Rajabi
    Anup Kasi
    Joaquina Baranda
    Weijing Sun
    Stephen Williamson
    Yu-Chiao Chiu
    Hatice Ulku Osmanbeyoglu
    Rashna Madan
    Hassan Abushukair
    Kelly Mulvaney
    Andrew K. Godwin
    Azhar Saeed
    Nature Communications, 15
12345